This is consistent with the fact that IL-1β–neutralizing treatment is effective in some but not all MKD patients (56, 63, 64), and therapies targeting IL-6 and TNF-α can also be beneficial (64). The gene discussed is IL6; the disease is mevalonic aciduria.